MBX 4291 — Interim data
Q4 2026
Results from the first cohort of the 12-week MAD portion of the Phase 1 clinical trial are expected in the fourth quarter of 2026.Source filing
MBX biotech catalysts & pipeline
MBX BIOSCIENCES INC · Data as of 2026-10-25
Upcoming catalysts
MBX 4291 — Topline data
2027
We look forward to topline results anticipated in 2027.Source filing
MBX 6180 — Conference presentation
Q4 2026
We expect to present preclinical data from MBX 6180 at a scientific meeting in the fourth quarter of 2026.Source filing